Cardio Diagnostics Holdings, Inc. announces that the Company will showcase its HeartRiskTM and Actionable Clinical IntelligenceTM platforms at the American College of Cardiology?s 73rd Annual Scientific Session (ACC.24), taking place in Atlanta, GA, from April 6-8, 2024. Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All." By harnessing the technology at the intersection of genomics, epigenomics, and artificial intelligence, the Company is advancing precision medicine in cardiology and improving the standard of cardiovascular medicine available to patients. All attendees including providers, provider organizations and potential industry partners will be able to learn more about Cardio Diagnostics' HeartRisk and Actionable Clinical Intelligence platforms at booth 3605.

The booth will feature live demonstrations and informative presentations that delve into the features and benefits of HeartRisk and Actionable Clinical Intelligence V.3, offering a hands-on experience with these transformative technologies. HeartRisk: HeartRisk is a cardiovascular risk intelligence platform customized to provide actionable insights to risk-bearing provider organizations and value-based cardiology groups to help better manage their shared-risk and value-based contracts by identifying and stratifying at-risk populations, and understanding the drivers of heart disease, ensuring quality measures and ratings are met. With HeartRisk, organizations have a new tool to support cost-containment initiatives and realize the value of risk-based contracts while better managing cardiovascular disease in their patient populations at scale.

Actionable Clinical Intelligence V.3: Building upon the success of its predecessor, which debuted at ACC in 2023, Actionable Clinical Intelligence V.3 takes precision medicine to new heights. Actionable Clinical Intelligence (ACI) is coupled to Cardio Diagnostics? clinical blood tests, Epi+Gen CHD and PrecisionCHD, to provide deeper and actionable insights to providers about factors contributing to their patient?s coronary heart disease.

At the heart of ACI is the ability for providers to measure the impact of lifestyle and therapeutic interventions on the underlying heart disease. Providers who are now better able to understand and monitor changes in heart attack risk and the progression of coronary heart disease with ACI, can be better equipped to implement personalized and dynamic prevention and treatment strategies for their patients.